The Drug Repurposing Market is expected to register a CAGR of 15% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Drug Repurposing Market report is segmented by disease indication into Oncology, CNS Diseases, and Neurodegenerative Diseases. The end-user segment includes Hospitals and Ambulatory Surgical Centers. The market evaluation is presented in US$ for the above segmental analysis. The global analysis is broken down at the regional level and major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Drug Repurposing Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Drug Repurposing Market Segmentation
Disease Indication- Oncology
- CNS Diseases
- Neurodegenerative diseases
- Hospitals
- Ambulatory Surgical Centers
Strategic Insights
Drug Repurposing Market Growth Drivers- Rising Healthcare Spending and Chronic Disease Prevalence: Rising global healthcare spending, along with the increasing prevalence of chronic diseases, continues to drive demand for new, cost-effective solutions for treating these diseases, fostering growth in the drug repurposing market.
- Accelerated Discovery through AI and Machine Learning: The rapidly increasing recognition of the potential of artificial intelligence and machine learning in drug discovery is accelerating the identification of new therapeutic applications for existing drugs.
- Demand for Personalized Medicine and Targeted Therapies: The growing interest in personalized or precision medicine is generating an environment that demands targeted therapies, where repurposing existing drugs holds great promise, particularly for managing rare diseases and inadequately served patient groups.
- Adoption of Artificial Intelligence and Machine Learning: The escalating adoption of artificial intelligence (AI) and machine learning (ML) will revolutionize new drug indications. Advanced algorithms can analyze vast datasets to unveil previously hidden patterns, identifying new therapeutic applications for existing drugs.
- Growing Importance of Personalized Medicine: The increasing emphasis on personalized medicine will drive the development of repurposed drugs that are targeted at specific patient populations. Genomic and patient-specific data will allow researchers to identify repurposed drugs suited to individual patients.
- Collaboration Across Pharmaceutical, Research, and Government Sectors: Collaboration between pharmaceutical companies, research institutions, and government agencies will accelerate the drug repurposing ecosystem. Sharing resources, expertise, and data will foster innovation and lead to more effective repurposed drugs.
- Meeting Unmet Medical Needs: Drug repurposing could address unsolved medical needs, particularly for rare diseases and underserved patient populations. Identifying new therapeutic applications for existing drugs would allow researchers to develop targeted therapies that may not have been previously considered.
- Growing Demand for Innovative Treatments: The rising prevalence of chronic diseases and an aging population creates a huge demand for innovative treatments. Drug repurposing offers an exciting opportunity to develop novel therapies that can improve patient outcomes and quality of life.
- Use of Artificial Intelligence and Machine Learning: The growing recognition of artificial intelligence (AI) and machine learning (ML) in drug discovery presents new opportunities for drug repurposing. These technologies can process vast amounts of biological and clinical data to identify potential new drug-target interactions, accelerating the development of new therapeutic applications for existing drugs.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Drug Repurposing Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Drug Repurposing Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The leading players of the market are: Astellas Pharma Inc., Biovista, Novartis AG, AbbVie Inc., Pfizer Inc., Allergan Plc., NuMedii, Abbott Healthcare, Hoffmann-La Roche, Johnson & Johnson.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
The increasing adoption of artificial intelligence and machine learning will revolutionize the identification of novel drug indications. Advanced algorithms can analyze vast datasets to uncover hidden patterns and potential therapeutic applications for existing drugs. Moreover, personalized medicine will increasingly drive the development of repurposed drugs tailored to specific patient populations. Genomic and other patient-specific data are leveraged for researchers to identify the best repurposed drugs suitable for a particular patient.
Drug Repurposing Market is expected to grow at a CAGR of 15% between 2023-2031
Several factors push the drug repurposing market forward. The global healthcare expense is increasing, and the prevalence of chronic diseases is rising that requires innovative and cost-effective therapeutic solutions. Repositioning existing drugs is an easier and more economical solution than traditional drug development. This growing awareness of the promise of artificial intelligence and machine learning in drug discovery has fast-tracked the identification of new therapeutic uses for already existing drugs. The two technologies allow researchers to process vast amounts of biological and clinical data to reveal novel drug-target interactions. Several trends are shaping the future of drug repurposing.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Drug Repurposing Market - By Disease Indication
1.3.2 Drug Repurposing Market - By End User
1.3.3 Drug Repurposing Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DRUG REPURPOSING MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. DRUG REPURPOSING MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. DRUG REPURPOSING MARKET - GLOBAL MARKET ANALYSIS
6.1. DRUG REPURPOSING - GLOBAL MARKET OVERVIEW
6.2. DRUG REPURPOSING - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. DRUG REPURPOSING MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
7.1. OVERVIEW
7.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
7.3. ONCOLOGY
7.3.1. Overview
7.3.2. Oncology Market Forecast and Analysis
7.4. CNS DISEASES
7.4.1. Overview
7.4.2. CNS Diseases Market Forecast and Analysis
7.5. NEURODEGENERATIVE DISEASES
7.5.1. Overview
7.5.2. Neurodegenerative diseases Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. DRUG REPURPOSING MARKET - REVENUE AND FORECASTS TO 2028 - END USER
8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
8.3.1. Overview
8.3.2. Hospitals Market Forecast and Analysis
8.4. AMBULATORY SURGICAL CENTERS
8.4.1. Overview
8.4.2. Ambulatory Surgical Centers Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. DRUG REPURPOSING MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Drug Repurposing Market Overview
9.1.2 North America Drug Repurposing Market Forecasts and Analysis
9.1.3 North America Drug Repurposing Market Forecasts and Analysis - By Disease Indication
9.1.4 North America Drug Repurposing Market Forecasts and Analysis - By End User
9.1.5 North America Drug Repurposing Market Forecasts and Analysis - By Countries
9.1.5.1 Canada Drug Repurposing Market
9.1.5.1.1 Canada Drug Repurposing Market by Disease Indication
9.1.5.1.2 Canada Drug Repurposing Market by End User
9.1.5.2 Mexico Drug Repurposing Market
9.1.5.2.1 Mexico Drug Repurposing Market by Disease Indication
9.1.5.2.2 Mexico Drug Repurposing Market by End User
9.1.5.3 US Drug Repurposing Market
9.1.5.3.1 US Drug Repurposing Market by Disease Indication
9.1.5.3.2 US Drug Repurposing Market by End User
9.2. EUROPE
9.2.1 Europe Drug Repurposing Market Overview
9.2.2 Europe Drug Repurposing Market Forecasts and Analysis
9.2.3 Europe Drug Repurposing Market Forecasts and Analysis - By Disease Indication
9.2.4 Europe Drug Repurposing Market Forecasts and Analysis - By End User
9.2.5 Europe Drug Repurposing Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Drug Repurposing Market
9.2.5.1.1 Germany Drug Repurposing Market by Disease Indication
9.2.5.1.2 Germany Drug Repurposing Market by End User
9.2.5.2 France Drug Repurposing Market
9.2.5.2.1 France Drug Repurposing Market by Disease Indication
9.2.5.2.2 France Drug Repurposing Market by End User
9.2.5.3 Italy Drug Repurposing Market
9.2.5.3.1 Italy Drug Repurposing Market by Disease Indication
9.2.5.3.2 Italy Drug Repurposing Market by End User
9.2.5.4 Spain Drug Repurposing Market
9.2.5.4.1 Spain Drug Repurposing Market by Disease Indication
9.2.5.4.2 Spain Drug Repurposing Market by End User
9.2.5.5 United Kingdom Drug Repurposing Market
9.2.5.5.1 United Kingdom Drug Repurposing Market by Disease Indication
9.2.5.5.2 United Kingdom Drug Repurposing Market by End User
9.2.5.6 Rest of Europe Drug Repurposing Market
9.2.5.6.1 Rest of Europe Drug Repurposing Market by Disease Indication
9.2.5.6.2 Rest of Europe Drug Repurposing Market by End User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Drug Repurposing Market Overview
9.3.2 Asia-Pacific Drug Repurposing Market Forecasts and Analysis
9.3.3 Asia-Pacific Drug Repurposing Market Forecasts and Analysis - By Disease Indication
9.3.4 Asia-Pacific Drug Repurposing Market Forecasts and Analysis - By End User
9.3.5 Asia-Pacific Drug Repurposing Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Drug Repurposing Market
9.3.5.1.1 Australia Drug Repurposing Market by Disease Indication
9.3.5.1.2 Australia Drug Repurposing Market by End User
9.3.5.2 China Drug Repurposing Market
9.3.5.2.1 China Drug Repurposing Market by Disease Indication
9.3.5.2.2 China Drug Repurposing Market by End User
9.3.5.3 India Drug Repurposing Market
9.3.5.3.1 India Drug Repurposing Market by Disease Indication
9.3.5.3.2 India Drug Repurposing Market by End User
9.3.5.4 Japan Drug Repurposing Market
9.3.5.4.1 Japan Drug Repurposing Market by Disease Indication
9.3.5.4.2 Japan Drug Repurposing Market by End User
9.3.5.5 South Korea Drug Repurposing Market
9.3.5.5.1 South Korea Drug Repurposing Market by Disease Indication
9.3.5.5.2 South Korea Drug Repurposing Market by End User
9.3.5.6 Rest of Asia-Pacific Drug Repurposing Market
9.3.5.6.1 Rest of Asia-Pacific Drug Repurposing Market by Disease Indication
9.3.5.6.2 Rest of Asia-Pacific Drug Repurposing Market by End User
9.4. SOUTH AND CENTRAL AMERICA
9.4.1 South and Central America Drug Repurposing Market Overview
9.4.2 South and Central America Drug Repurposing Market Forecasts and Analysis
9.4.3 South and Central America Drug Repurposing Market Forecasts and Analysis - By Disease Indication
9.4.4 South and Central America Drug Repurposing Market Forecasts and Analysis - By End User
9.4.5 South and Central America Drug Repurposing Market Forecasts and Analysis - By Countries
9.4.5.1 Brazil Drug Repurposing Market
9.4.5.1.1 Brazil Drug Repurposing Market by Disease Indication
9.4.5.1.2 Brazil Drug Repurposing Market by End User
9.4.5.2 Argentina Drug Repurposing Market
9.4.5.2.1 Argentina Drug Repurposing Market by Disease Indication
9.4.5.2.2 Argentina Drug Repurposing Market by End User
9.4.5.3 Rest of South and Central America Drug Repurposing Market
9.4.5.3.1 Rest of South and Central America Drug Repurposing Market by Disease Indication
9.4.5.3.2 Rest of South and Central America Drug Repurposing Market by End User
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL DRUG REPURPOSING MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. DRUG REPURPOSING MARKET, KEY COMPANY PROFILES
12.1. ASTELLAS PHARMA INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BIOVISTA
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ABBVIE INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ALLERGAN PLC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NUMEDII
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ABBOTT HEALTHCARE
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. HOFFMANN-LA ROCHE
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. JOHNSON & JOHNSON
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Astellas Pharma Inc.
2. Biovista
3. Novartis AG
4. AbbVie Inc.
5. Pfizer Inc.
6. Allergan Plc.
7. NuMedii
8. Abbott Healthcare
9. Hoffmann-La Roche
10. Johnson & Johnson
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For